DEF 14A: SeaStar Medical Seeks Reverse Split, Share Reduction

SeaStar Medical Holding Corporation is seeking stockholder approval for a 1-for-10 reverse stock split and a reduction in authorized common shares to maintain Nasdaq listing and support future growth.

Summary

• Stockholders are asked to approve a 1-for-10 reverse stock split of common stock, to be effected at the Board's discretion within one year of the Special Meeting.
• The reverse stock split aims to increase the common stock's bid price to meet Nasdaq's $1.00 minimum requirement, attract investors, and provide flexibility for future equity financings.
• The Company received a Nasdaq deficiency letter on August 6, 2025, due to its closing bid price being below $1.00 for 30 consecutive business days; the stock closed at $0.5506 per share on November 3, 2025.
• Stockholders are also asked to approve a reduction in the number of authorized common shares by 25,000,000, from 450,000,000 to 425,000,000 shares.
• This reduction in authorized shares is intended to mitigate potential dilution, provide sufficient flexibility for future needs, and reduce annual Delaware franchise tax obligations by an estimated $4,000.
• A proposal to adjourn or postpone the Special Meeting is also on the agenda, if necessary, to secure sufficient votes for the other proposals.
• As of the Record Date (November 3, 2025), there were 35,865,834 shares of Common Stock outstanding and entitled to vote.
• If the reverse stock split is implemented, approximately 3,586,584 shares of Common Stock would be outstanding, and fractional shares will be rounded up to the nearest whole share.
• The Board of Directors unanimously recommends voting FOR all three proposals.

Sentiment

Score: 5

Explanation: The proposals are reactive to existing challenges (Nasdaq deficiency, future funding needs) but represent necessary and proactive steps to address these issues and maintain market viability. The reduction in authorized shares is a positive governance move. Overall, the sentiment is neutral to slightly negative, reflecting the underlying challenges while acknowledging the company's efforts to mitigate them.

Positives

• The proposed reverse stock split aims to maintain the company's listing on The Nasdaq Capital Market, avoiding the adverse consequences of delisting.
• A higher stock price post-split may generate increased investor interest and help attract and retain employees.
• The reduction in authorized shares will decrease annual Delaware franchise tax obligations by an estimated $4,000.
• Rounding up of fractional shares in the reverse stock split benefits stockholders who would otherwise receive fractional shares.
• The reverse stock split is expected to provide greater flexibility for future equity financings to support anticipated growth.

Negatives

• There is no assurance that the reverse stock split will result in a sustained increase in the per share price or that the market price will rise proportionally.
• The liquidity of the common stock could be adversely affected by the reduced number of shares outstanding after the reverse stock split.
• The increased proportion of unissued authorized shares to issued shares could, under certain circumstances, have an anti-takeover effect.
• The company believes it will require additional funding sources to fund its operations, potentially in 2026, indicating ongoing financial needs.
• There is a risk that the proposed 425,000,000 authorized shares may not be sufficient for future needs, potentially forcing the company to seek additional stockholder approval, which could be time-consuming or denied.

Risks

• Failure to regain compliance with Nasdaq's $1.00 minimum bid price requirement could lead to delisting from The Nasdaq Capital Market.
• Delisting would likely result in trading on over-the-counter markets, reducing liquidity, making it less convenient for investors to trade, and potentially negatively impacting the market price, ability to raise capital, and employee equity awards.
• The reverse stock split may not result in a sustained increase in the per share price of common stock.
• The market price per share after the reverse stock split may not rise in proportion to the reduction in the number of shares outstanding.
• The reverse stock split may not attract brokers and investors who do not trade in lower-priced stocks, nor may it increase the company's ability to attract and retain employees.
• The market price per share may not achieve the $1.00 minimum bid price requirement for a sufficient period to regain compliance for continued listing on Nasdaq.
• The liquidity of the common stock could be adversely affected by the reduced number of shares that would be outstanding after the reverse stock split.
• Future issuances of common stock or securities convertible into common stock could have a negative impact on earnings per share and book value per share, and dilute the voting power and ownership of existing stockholders.
• The availability of a substantial number of authorized but unissued shares of common stock could, under certain circumstances, discourage or make more difficult efforts to obtain control of the company.
• The company anticipates requiring additional funding sources to fund its operations, potentially during 2026, and there is no guarantee such funding will be secured on favorable terms or at all.
• If the proposed 425,000,000 authorized shares prove insufficient, obtaining future stockholder approval for an increase could be time-consuming or unsuccessful, limiting the company's flexibility and prospects.

Future Outlook

The company believes that additional funding sources will be required to fund its operations, potentially during 2026. The Board believes that 425,000,000 authorized shares of common stock will provide sufficient flexibility for expected purposes in the foreseeable future, including equity financings and attracting/retaining employees.

Management Comments

• "Whether or not you attend the Special Meeting, it is important that your shares and votes are represented. Therefore, I urge you to promptly vote." Eric Schlorff, Director and Chief Executive Officer.
• "Promptly voting your shares will ensure the presence of a quorum at the Special Meeting and will save us the expense of further solicitation." Eric Schlorff, Chief Executive Officer.

Industry Context

The proposed reverse stock split is a common strategy employed by companies facing minimum bid price deficiencies to maintain their listing on major exchanges like Nasdaq. This action is critical for market visibility, liquidity, and access to capital markets, which are vital for smaller biotechnology or medical device companies like SeaStar Medical. The reduction in authorized shares, while less common, reflects a proactive governance measure to manage potential dilution and reduce administrative costs, aligning with broader trends of optimizing capital structure.

Comparison to Industry Standards

• The filing does not provide specific comparisons to other companies, projects, or industry benchmarks regarding the effectiveness of reverse stock splits or authorized share reductions.
• The company acknowledges that the history of similar stock split combinations for companies in like circumstances is varied, indicating no guaranteed outcome compared to industry peers.

Corporate Governance

Stakeholder Impact

• Shareholders: Will hold fewer shares but at a proportionally higher price per share (if successful), with fractional shares rounded up. Their percentage ownership will remain largely the same. Potential for improved liquidity and investor interest, but also risk of further price decline post-split. Future equity financings could lead to dilution.
• Employees: Maintaining Nasdaq listing and a higher stock price could make equity awards more attractive, aiding in talent attraction and retention.
• Company: Benefits from maintaining Nasdaq listing, avoiding delisting consequences, gaining flexibility for future capital raises, and reducing administrative costs (Delaware franchise tax).
• Creditors/Lenders: Improved market standing and access to equity financing could enhance the company's financial stability, potentially benefiting creditors.

Next Steps

• Stockholders are urged to vote on the proposals by December 18, 2025, at the Special Meeting.
• If approved, the Board of Directors will have the sole discretion to effect the reverse stock split at any time within one year of the Special Meeting.
• The company intends to file the certificate of amendment for the authorized share reduction with the Secretary of State of Delaware promptly after the Special Meeting, if approved.
• The company plans to announce preliminary voting results at the Special Meeting and report final results in a Current Report on Form 8-K with the SEC.
• The company anticipates requiring additional funding sources to fund its operations during 2026.
• Stockholders intending to submit proposals for the 2026 annual meeting must do so by January 21, 2026.
• Stockholders intending to nominate directors for the 2026 annual meeting must provide notice between March 5, 2026, and April 4, 2026.

Key Dates

Recommendation

The company is taking essential, albeit reactive, steps to address its Nasdaq listing compliance and prepare for future capital requirements. These actions are crucial for the company's continued operation and market access. However, they do not inherently signal strong operational performance or immediate growth. The success of the reverse stock split in sustaining a higher share price and attracting new investors is uncertain, and the need for future funding indicates ongoing financial challenges. Investors should hold to monitor the effectiveness of these strategic measures and the company's progress in its core business.

Keywords

Reverse Stock Split, Nasdaq Listing Compliance, Authorized Shares Reduction, Equity Financing, Corporate Governance, Stockholder Meeting, SEC Filing, DEF 14A, SeaStar Medical